Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 183

1.

Growth hormone (GH) effects on bone and collagen turnover in healthy adults and its potential as a marker of GH abuse in sports: a double blind, placebo-controlled study. The GH-2000 Study Group.

Longobardi S, Keay N, Ehrnborg C, Cittadini A, Rosén T, Dall R, Boroujerdi MA, Bassett EE, Healy ML, Pentecost C, Wallace JD, Powrie J, Jørgensen JO, Saccà L.

J Clin Endocrinol Metab. 2000 Apr;85(4):1505-12.

PMID:
10770189
2.

Bone mineral content and bone metabolism during physiological GH treatment in GH-deficient adults--an 18-month randomised, placebo-controlled, double blinded trial.

Sneppen SB, Hoeck HC, Kollerup G, Sørensen OH, Laurberg P, Feldt-Rasmussen U.

Eur J Endocrinol. 2002 Feb;146(2):187-95.

3.

Treatment with the oral growth hormone secretagogue MK-677 increases markers of bone formation and bone resorption in obese young males.

Svensson J, Ohlsson C, Jansson JO, Murphy G, Wyss D, Krupa D, Cerchio K, Polvino W, Gertz B, Baylink D, Mohan S, Bengtsson BA.

J Bone Miner Res. 1998 Jul;13(7):1158-66.

4.

Evaluation of the optimum dose of growth hormone (GH) for restoring bone mass in adult-onset GH deficiency: results from two 12-month randomized studies.

Abrahamsen B, Hangaard J, Horn HC, Hansen TB, Gregersen G, Hansen-Nord M, Vahl N, Junker P, Andersen M, Hagen C.

Clin Endocrinol (Oxf). 2002 Aug;57(2):273-81.

PMID:
12153608
5.

Dose-dependent effects of recombinant human growth hormone on biochemical markers of bone and collagen metabolism in adult growth hormone deficiency.

Bollerslev J, Møller J, Thomas S, Djøseland O, Christiansen JS.

Eur J Endocrinol. 1996 Dec;135(6):666-71.

PMID:
9025710
6.

Responses of markers of bone and collagen turnover to exercise, growth hormone (GH) administration, and GH withdrawal in trained adult males.

Wallace JD, Cuneo RC, Lundberg PA, Rosén T, Jørgensen JO, Longobardi S, Keay N, Sacca L, Christiansen JS, Bengtsson BA, Sönksen PH.

J Clin Endocrinol Metab. 2000 Jan;85(1):124-33.

PMID:
10634375
7.

Biochemical markers of bone turnover in tibia fracture patients randomly assigned to growth hormone (GH) or placebo injections: Implications for detection of GH abuse.

Krusenstjerna-Hafstrøm T, Rasmussen MH, Raschke M, Govender S, Madsen J, Christiansen JS.

Growth Horm IGF Res. 2011 Dec;21(6):331-5. doi: 10.1016/j.ghir.2011.08.003. Epub 2011 Oct 1.

PMID:
21963127
8.

Effects of a growth hormone receptor antagonist on bone markers in acromegaly.

Fairfield WP, Sesmilo G, Katznelson L, Pulaski K, Freda PU, Stavrou S, Kleinberg D, Klibanski A.

Clin Endocrinol (Oxf). 2002 Sep;57(3):385-90.

PMID:
12201832
9.

Effects of two years of growth hormone (GH) replacement therapy on bone metabolism and mineral density in childhood and adulthood onset GH deficient patients.

Longobardi S, Di Rella F, Pivonello R, Di Somma C, Klain M, Maurelli L, Scarpa R, Colao A, Merola B, Lombardi G.

J Endocrinol Invest. 1999 May;22(5):333-9.

PMID:
10401706
10.
11.

Effects of 12 months rec-GH therapy on bone and collagen turnover and bone mineral density in GH deficient children with thalassaemia major.

Sartorio A, Conte G, Conti A, Masala A, Alagna S, Rovasio P, Faglia G.

J Endocrinol Invest. 2000 Jun;23(6):356-61.

PMID:
10908162
12.

Elite volunteer athletes of different sport disciplines may have elevated baseline GH levels divorced from unaltered levels of both IGF-I and GH-dependent bone and collagen markers: a study on-the-field.

Sartorio A, Marazzi N, Agosti F, Faglia G, Corradini C, De Palo E, Cella S, Rigamonti A, Muller EE.

J Endocrinol Invest. 2004 May;27(5):410-5.

PMID:
15279071
13.

Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group.

Murphy MG, Bach MA, Plotkin D, Bolognese J, Ng J, Krupa D, Cerchio K, Gertz BJ.

J Bone Miner Res. 1999 Jul;14(7):1182-8.

14.

Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.

Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J, Krupa D, Gertz BJ; MK-677/Alendronate Study Group.

J Clin Endocrinol Metab. 2001 Mar;86(3):1116-25.

PMID:
11238495
15.

Effects of intensive chemotherapy on bone and collagen turnover and the growth hormone axis in children with acute lymphoblastic leukemia.

Crofton PM, Ahmed SF, Wade JC, Stephen R, Elmlinger MW, Ranke MB, Kelnar CJ, Wallace WH.

J Clin Endocrinol Metab. 1998 Sep;83(9):3121-9.

PMID:
9745414
16.

Combined evaluation of resting IGF1, N-terminal propeptide of type III procollagen and C-terminal cross-linked telopeptide of type I collagen levels might be useful for detecting inappropriate GH administration in female athletes.

Di Luigi L, Rigamonti AE, Agosti F, Mencarelli M, Sgrò P, Marazzi N, Cella SG, Müller EE, Sartorio A.

Eur J Endocrinol. 2009 May;160(5):753-8. doi: 10.1530/EJE-08-0884. Epub 2009 Mar 3.

17.

A cross-sectional study on biochemical parameters of bone turnover and vitamin d metabolites in healthy dutch children and young adults.

van der Sluis IM, Hop WC, van Leeuwen JP, Pols HA, de Muinck Keizer-Schrama SM.

Horm Res. 2002;57(5-6):170-9.

PMID:
12053089
18.

Effects of 42 months of GH treatment on bone mineral density and bone turnover in GH-deficient adults.

Välimäki MJ, Salmela PI, Salmi J, Viikari J, Kataja M, Turunen H, Soppi E.

Eur J Endocrinol. 1999 Jun;140(6):545-54.

19.
20.

The effects of prolonged growth hormone replacement on bone metabolism and bone mineral density in hypopituitary adults.

Beshyah SA, Kyd P, Thomas E, Fairney A, Johnston DG.

Clin Endocrinol (Oxf). 1995 Mar;42(3):249-54.

PMID:
7758229

Supplemental Content

Support Center